Company

Relevant Interviews, Disease and Trial Updates and Stock-Markets News posted by CRISPR Medicine News

Check also companies to follow in 2022 and CMN Markets for the latest stock and market trends

Regeneron Pharmaceuticals

Main (gene editing) focus: Gene editing for genetic diseases

Company stage: Commercial

Diseases: Transthyretin (ATTR) Amyloidosis, hemophilia A and B, multiple undisclosed

Genome editing tool: CRISPR-Cas9

Funding stage: Public (NASDAQ: REGN)

Location: Tarrytown, NY, USA

Website: https://www.regeneron.com/

Pipeline: https://www.regeneron.com/science/pipeline

Partners: Intellia Therapeutics

Regeneron is a public, large pharma company that has been in operation since 1988. The company is focusing on a broad range of diseases, but has recently struck up a partnership deal with Intellia Therapeutics. Together, the two companies are developing both in vivo and ex vivo based therapies. The most advanced programme, NTLA-2001 is being developed as a one-time, in vivo treatment for Transthyretin (ATTR) Amyloidosis.

Tags

HashtagRegeneron Pharmaceuticals, Inc.

Company: Regeneron Pharmaceuticals
close
Search CRISPR Medicine